<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Health Qual Life Outcomes</journal-id><journal-title-group><journal-title>Health and Quality of Life Outcomes</journal-title></journal-title-group><issn pub-type="epub">1477-7525</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21771304</article-id><article-id pub-id-type="pmc">3150240</article-id><article-id pub-id-type="publisher-id">1477-7525-9-54</article-id><article-id pub-id-type="doi">10.1186/1477-7525-9-54</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Stress-related psycho-physiological disorders: randomized single blind placebo controlled naturalistic study of psychometric evaluation using a radio electric asymmetric treatment</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Rinaldi</surname><given-names>Salvatore</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>srinaldi@irf.it</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Fontani</surname><given-names>Vania</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>vfontani@irf.it</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Aravagli</surname><given-names>Lucia</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>laravagli@irf.it</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Mannu</surname><given-names>Piero</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>pmannu@irf.it</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Castagna</surname><given-names>Alessandro</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>acasta@irf.it</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Margotti</surname><given-names>Matteo Lotti</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>mlottimargotti@irf.it</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Rosettani</surname><given-names>Barbara</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>barbra.ross@googlemail.com</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Neuro-Psycho-Physio Pathology and Neuro Psycho Physical Optimization, Rinaldi Fontani Institute, Viale Belfiore 43, Florence 50144, Italy</aff><aff id="I2"><label>2</label>Medical School of Occupational Medicine, University of Florence, Largo Piero Palagi, Florence, 50139, Italy</aff><pub-date pub-type="collection"><year>2011</year></pub-date><pub-date pub-type="epub"><day>19</day><month>7</month><year>2011</year></pub-date><volume>9</volume><fpage>54</fpage><lpage>54</lpage><history><date date-type="received"><day>3</day><month>7</month><year>2010</year></date><date date-type="accepted"><day>19</day><month>7</month><year>2011</year></date></history><permissions><copyright-statement>Copyright ©2011 Rinaldi et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2011</copyright-year><copyright-holder>Rinaldi et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.hqlo.com/content/9/1/54"></self-uri><abstract><sec><title><offsets xml_i="4028" xml_f="4038" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="4049" xml_f="4478" txt_i="22" txt_f="451">The aim of this study is to investigate the effects of a radio electric asymmetric treatment on psycho-physiological disorders (PPD). PPD are often stress related and are under the unconscious control of the patient and cannot be traced back to any serious physical disease. The brain stimulation treatment protocol used is called Neuro Psycho Physical Optimization (NPPO) with a Radio Electric Asymmetric Conveyer (REAC) device.</offsets></p></sec><sec><title><offsets xml_i="4500" xml_f="4507" txt_i="453" txt_f="460">Methods</offsets></title><p><offsets xml_i="4518" xml_f="4760" txt_i="461" txt_f="703">Psychological stress and PPD were measured for a group of 888 subjects using the Psychological Stress Measure (PSM) test, a self-administered questionnaire. Data were collected immediately before and after the 4-weeks of REAC treatment cycle.</offsets></p></sec><sec><title><offsets xml_i="4782" xml_f="4789" txt_i="705" txt_f="712">Results</offsets></title><p><offsets xml_i="4800" xml_f="5141" txt_i="713" txt_f="1054">This study showed a significant reduction in scores measuring subjective perceptions of stress for subjects treated with a cycle of NPPO REAC treatment. At the end-point the number of subjects reporting symptoms of stress-related PPD on the PSM test was significantly reduced, whereas in the placebo group the difference was not significant.</offsets></p></sec><sec><title><offsets xml_i="5163" xml_f="5173" txt_i="1056" txt_f="1066">Conclusion</offsets></title><p><offsets xml_i="5184" xml_f="5323" txt_i="1067" txt_f="1206">A cycle of NPPO treatment with REAC was shown to reduce subjective perceptions of stress measured by the PSM test and in particular on PPD.</offsets></p></sec><sec><title><offsets xml_i="5345" xml_f="5363" txt_i="1208" txt_f="1226">Trial Registration</offsets></title><p><offsets xml_i="5374" xml_f="5486" txt_i="1227" txt_f="1339">This trial has been registered in the Australian New Zealand Clinical Trials Registry (ANZCTR) with the number: </offsets><ext-link ext-link-type="uri" xlink:href="http://www.anzctr.org.au/ACTRN12607000463471.aspx"><offsets xml_i="5579" xml_f="5598" txt_i="1339" txt_f="1358">ACTRN12607000463471</offsets></ext-link><offsets xml_i="5609" xml_f="5610" txt_i="1358" txt_f="1359">.</offsets></p></sec></abstract></article-meta></front><body><sec><title><offsets xml_i="5672" xml_f="5682" txt_i="1368" txt_f="1378">Background</offsets></title><p><offsets xml_i="5693" xml_f="6143" txt_i="1379" txt_f="1829">A high proportion of patients with general distress were suffering only from PPD (also known as "Psychosomatic disorders" or "maladaptive illness") classified as "psychological factors affecting medical condition" in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR, APA, 2000) (code 777). PPD are characterized by psychological and physical symptoms that are caused by stress and emotional factors and involve one o more systems.</offsets></p><p><offsets xml_i="6150" xml_f="6309" txt_i="1830" txt_f="1989">The physiological changes involved are those that normally are related with specific emotional states, but in PPD these changes are more intense and sustained.</offsets></p><p><offsets xml_i="6316" xml_f="6658" txt_i="1990" txt_f="2332">Common PPD include insomnia, temporal-mandibular joint problems (in particular joint pain), migraine headaches, tension headaches, attention deficit and hyperactivity disorder (ADHD), arthritis, functional diarrhea, ulcerative colitis, essential hypertension, asthma and primary dysmenorrhoea. These symptoms are often medically unexplained [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="6689" xml_f="6690" txt_i="2332" txt_f="2333">1</offsets></xref><offsets xml_i="6697" xml_f="6698" txt_i="2333" txt_f="2334">,</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="6729" xml_f="6730" txt_i="2334" txt_f="2335">2</offsets></xref><offsets xml_i="6737" xml_f="6956" txt_i="2335" txt_f="2554">] and often difficult to treat. The purpose of this work is to verify if the use of NPPO REAC treatment was effective in reducing subjective perceptions of stress as measured by a validated questionnaire, the PSM test [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="6987" xml_f="6988" txt_i="2554" txt_f="2555">3</offsets></xref><offsets xml_i="6995" xml_f="6996" txt_i="2555" txt_f="2556">,</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="7027" xml_f="7028" txt_i="2556" txt_f="2557">4</offsets></xref><offsets xml_i="7035" xml_f="7133" txt_i="2557" txt_f="2655">]. This questionnaire allows to classify the stress-level and the stress-related symptoms of PPD [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="7164" xml_f="7165" txt_i="2655" txt_f="2656">5</offsets></xref><offsets xml_i="7172" xml_f="7190" txt_i="2656" txt_f="2674">] of the subjects.</offsets></p></sec><sec sec-type="materials|methods"><title><offsets xml_i="7241" xml_f="7262" txt_i="2676" txt_f="2697">Methods and Materials</offsets></title><p><offsets xml_i="7273" xml_f="7507" txt_i="2698" txt_f="2932">The study was performed in accordance with the Declaration of Helsinki, with the Società di Ottimizzazione Neuro Psico Fisica e CRM Terapia's institutional ethics committee approval, and all subjects provided written informed consent.</offsets></p><sec><title><offsets xml_i="7523" xml_f="7535" txt_i="2933" txt_f="2945">Participants</offsets></title><p><offsets xml_i="7546" xml_f="7691" txt_i="2946" txt_f="3091">888 subjects were included in the study from an initial group of 1453 of patients who attended the Rinaldi-Fontani Institute in Florence, Italy (</offsets><italic><offsets xml_i="7699" xml_f="7715" txt_i="3091" txt_f="3107">Additional file </offsets></italic><xref ref-type="supplementary-material" rid="S1"><offsets xml_i="7773" xml_f="7774" txt_i="3107" txt_f="3108">1</offsets></xref><offsets xml_i="7781" xml_f="8134" txt_i="3108" txt_f="3461">). These patients showed different types of stress-related PPD such as tension and migraine headaches, essential hypertension, anxious tremors, colitis, irritable bowel syndrome, bruxism, neck and back pain, chronic pain syndrome, bronchial asthma, peptic ulcer disease, skin disorders and insomnia. Subjects were not taking any psychotropic medication.</offsets></p></sec><sec><title><offsets xml_i="8156" xml_f="8185" txt_i="3463" txt_f="3492">Sample size and randomization</offsets></title><p><offsets xml_i="8196" xml_f="8379" txt_i="3493" txt_f="3676">This is a naturalistic study therefore patients, with any type of stress-related pathology, came spontaneously to our medical centre and were observed in the normal clinical practice.</offsets></p><p><offsets xml_i="8386" xml_f="8768" txt_i="3677" txt_f="4059">In order to have a group of control for comparing the results from the treated patients, two groups were created. Therefore, subjects were randomly selected for each group with a simple computerized randomization by an external operator. and were divided into 2 groups: Group A subjects receiving active treatment and Group B subjects receiving placebo treatment in a specific room.</offsets></p><p><offsets xml_i="8775" xml_f="8963" txt_i="4060" txt_f="4248">Even if this study took place in Italy with Italian investigators, we could not find an Italian registry in the World Health Organization - International Clinical Trials Registry Platform </offsets><ext-link ext-link-type="uri" xlink:href="http://www.who.int/ictrp/network/primary/en/index.html"><offsets xml_i="9061" xml_f="9115" txt_i="4248" txt_f="4302">http://www.who.int/ictrp/network/primary/en/index.html</offsets></ext-link><offsets xml_i="9126" xml_f="9269" txt_i="4302" txt_f="4445">. Therefore we decided to select the first in the list that was the Australian New Zealand Clinical Trial Registry (ANZCTR) and registered (n° </offsets><ext-link ext-link-type="uri" xlink:href="http://www.anzctr.org.au/ACTRN12607000463471.aspx"><offsets xml_i="9362" xml_f="9381" txt_i="4445" txt_f="4464">ACTRN12607000463471</offsets></ext-link><offsets xml_i="9392" xml_f="9394" txt_i="4464" txt_f="4466">).</offsets></p></sec><sec><title><offsets xml_i="9416" xml_f="9443" txt_i="4468" txt_f="4495">Demographic characteristics</offsets></title><p><offsets xml_i="9454" xml_f="9861" txt_i="4496" txt_f="4903">Group A included 688 subjects: 401 (58,28%) females, average age 42.3 ± 11.3 yrs, and 287 (41,71%) males, average age 41.1 ± 11.4 yrs. These patients were treated with a cycle of NPPO of "active" REAC. Group B included 200 subjects: 123(61,5%) females, average age 48.8 ± 19.4 yrs, and 77 (38,5%) males, average age 45.8 ± 18.5 yrs. These patients were treated with a cycle of NPPO of "Placebo" REAC. Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="9893" xml_f="9894" txt_i="4903" txt_f="4904">1</offsets></xref><offsets xml_i="9901" xml_f="9902" txt_i="4904" txt_f="4905">.</offsets></p><table-wrap id="T1" position="float"><label><offsets xml_i="9950" xml_f="9957" txt_i="4906" txt_f="4913">Table 1</offsets></label><caption><p><offsets xml_i="9977" xml_f="10004" txt_i="4913" txt_f="4940">Demographic characteristics</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th align="left"><offsets xml_i="10092" xml_f="10099" txt_i="4941" txt_f="4948">Group A</offsets></th><th align="left"><offsets xml_i="10121" xml_f="10128" txt_i="4948" txt_f="4955">Group B</offsets></th><th align="left"><offsets xml_i="10150" xml_f="10155" txt_i="4955" txt_f="4960">Total</offsets></th></tr></thead><tbody><tr><td align="left"><bold><offsets xml_i="10207" xml_f="10210" txt_i="4960" txt_f="4963">Sex</offsets></bold></td><td></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="10275" xml_f="10282" txt_i="4967" txt_f="4974"> Female</offsets></td><td align="left"><offsets xml_i="10304" xml_f="10316" txt_i="4975" txt_f="4987">401 (58,28%)</offsets></td><td align="left"><offsets xml_i="10338" xml_f="10347" txt_i="4988" txt_f="4997">123 (62%)</offsets></td><td align="left"><offsets xml_i="10369" xml_f="10383" txt_i="4998" txt_f="5012">688 (100%) (A)</offsets></td></tr><tr><td align="left"><offsets xml_i="10414" xml_f="10419" txt_i="5013" txt_f="5018"> Male</offsets></td><td align="left"><offsets xml_i="10441" xml_f="10453" txt_i="5019" txt_f="5031">287 (41,71%)</offsets></td><td align="left"><offsets xml_i="10475" xml_f="10483" txt_i="5032" txt_f="5040">77 (%39)</offsets></td><td align="left"><offsets xml_i="10505" xml_f="10519" txt_i="5041" txt_f="5055">200 (100%) (B)</offsets></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left"><bold><offsets xml_i="10595" xml_f="10598" txt_i="5057" txt_f="5060">Age</offsets></bold></td><td></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="10663" xml_f="10665" txt_i="5064" txt_f="5066"> N</offsets></td><td align="left"><offsets xml_i="10687" xml_f="10690" txt_i="5067" txt_f="5070">688</offsets></td><td align="left"><offsets xml_i="10712" xml_f="10715" txt_i="5071" txt_f="5074">200</offsets></td><td align="left"><offsets xml_i="10737" xml_f="10740" txt_i="5075" txt_f="5078">888</offsets></td></tr><tr><td align="left"><offsets xml_i="10771" xml_f="10776" txt_i="5079" txt_f="5084"> Mean</offsets></td><td align="left"><offsets xml_i="10798" xml_f="10802" txt_i="5085" txt_f="5089">41,8</offsets></td><td align="left"><offsets xml_i="10824" xml_f="10828" txt_i="5090" txt_f="5094">47,7</offsets></td><td align="left"><offsets xml_i="10850" xml_f="10855" txt_i="5095" txt_f="5100">43,13</offsets></td></tr><tr><td align="left"><offsets xml_i="10886" xml_f="10889" txt_i="5101" txt_f="5104"> SD</offsets></td><td align="left"><offsets xml_i="10911" xml_f="10916" txt_i="5105" txt_f="5110">11,35</offsets></td><td align="left"><offsets xml_i="10938" xml_f="10943" txt_i="5111" txt_f="5116">19,14</offsets></td><td align="left"><offsets xml_i="10965" xml_f="10970" txt_i="5117" txt_f="5122">13,71</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="11016" xml_f="11063" txt_i="5123" txt_f="5170">Table legend text. Demographic characteristics.</offsets></p></table-wrap-foot></table-wrap></sec><sec><title><offsets xml_i="11116" xml_f="11161" txt_i="5172" txt_f="5217">Psychological test and psychiatric assessment</offsets></title><p><offsets xml_i="11172" xml_f="11212" txt_i="5218" txt_f="5258">The Psychological Stress Measure (PSM) [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="11243" xml_f="11244" txt_i="5258" txt_f="5259">3</offsets></xref><offsets xml_i="11251" xml_f="11252" txt_i="5259" txt_f="5260">,</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="11283" xml_f="11284" txt_i="5260" txt_f="5261">4</offsets></xref><offsets xml_i="11291" xml_f="11292" txt_i="5261" txt_f="5262">,</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="11323" xml_f="11324" txt_i="5262" txt_f="5263">6</offsets></xref><offsets xml_i="11331" xml_f="12879" txt_i="5263" txt_f="6811">] was specifically developed to detect the stress levels in non-clinical population. The PSM is usually a 49 items self-report paper and pencil questionnaire; but in this study we used an electronic version to collect and process the data, and to analyze the results. Each item is based on clusters of stress conditions: loss of self-control, irritability, psycho-physiological disorders, confusion, anxiety, depression, physical pain, hyperactivity and agitation. Patients were asked to answer the questions about their psychological stress using a 4-points scale to describe the intensity of their condition (very much = 4, much = 3, little = 2, none = 1). The final score is expressed in Total Points (TP). Furthermore, in order to detect the presence of the PPD symptoms, scores obtained from items hearing voices that other people do not hear (16), feeling afraid to go out of your house alone (25), your feelings being easily hurt (34), nausea or upset stomach (40) were specifically used. Both groups of subjects were clinically evaluated at t0 (before treatment) and t1 (after treatment) by a psychiatrist. At baseline and in the total of the sample, the mainly psychiatric diagnosis (according with DSMIV-TR) have been "subthreshold" forms of Generalized Anxiety Disorder (N = 557 patients) and Anxiety Disorder Not Otherwise Specified (NOS) (N = 114). After the treatment, all the symptoms of these mild clinical conditions have shown a remarkable improvement. In the remaining 217 subjects non relevant clinical aspect has been detected.</offsets></p><p><offsets xml_i="12886" xml_f="13112" txt_i="6812" txt_f="7038">Six-hundred-eighty-eight subjects (average PSM test total scores 122.53 ± 6.75) were treated with NPPO REAC therapy; 200 (average PSM test total scores 122.96 ± 7.041) were treated with "placebo NPPO REAC" and used as control.</offsets></p></sec><sec><title><offsets xml_i="13134" xml_f="13210" txt_i="7040" txt_f="7116">Description of the REAC and of the brain stimulation treatment protocol NPPO</offsets></title><p><offsets xml_i="13221" xml_f="13263" txt_i="7117" txt_f="7159">The REAC is an innovative medical device [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="13294" xml_f="13295" txt_i="7159" txt_f="7160">7</offsets></xref><offsets xml_i="13302" xml_f="13303" txt_i="7160" txt_f="7161">,</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="13334" xml_f="13335" txt_i="7161" txt_f="7162">8</offsets></xref><offsets xml_i="13342" xml_f="13516" txt_i="7162" txt_f="7336">] aimed to promote a reduction of the dysfunctional modifications in the Nervous System induced by stress and psychological factors, as reported by several medical articles [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="13547" xml_f="13548" txt_i="7336" txt_f="7337">9</offsets></xref><offsets xml_i="13555" xml_f="13556" txt_i="7337" txt_f="7338">-</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="13588" xml_f="13590" txt_i="7338" txt_f="7340">20</offsets></xref><offsets xml_i="13597" xml_f="13741" txt_i="7340" txt_f="7484">]. The REAC brain stimulation protocol treatment consists in a cycle of 18 NPPO sessions, applied in specific points of the auricular pavilion [</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="13773" xml_f="13775" txt_i="7484" txt_f="7486">10</offsets></xref><offsets xml_i="13782" xml_f="13981" txt_i="7486" txt_f="7685">]. The REAC treatment is simple, rapid, non-invasive and applied without pain. The instrument that we used is registered under the trademark Convogliatore di Radianza Modulante - CRM by ASMED, Italy.</offsets></p></sec><sec><title><offsets xml_i="14003" xml_f="14023" txt_i="7687" txt_f="7707">Statistical analysis</offsets></title><p><offsets xml_i="14034" xml_f="14123" txt_i="7708" txt_f="7797">Statistical analysis was performed using the Number Needed to Treat Analysis (NNT) Table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="14155" xml_f="14156" txt_i="7797" txt_f="7798">2</offsets></xref><offsets xml_i="14163" xml_f="14274" txt_i="7798" txt_f="7909">. For comparing total points before and after the treatment (placebo), the Wilcoxon Signed Rank Test was used (</offsets><italic><offsets xml_i="14282" xml_f="14298" txt_i="7909" txt_f="7925">Additional file </offsets></italic><xref ref-type="supplementary-material" rid="S2"><offsets xml_i="14356" xml_f="14357" txt_i="7925" txt_f="7926">2</offsets></xref><italic><offsets xml_i="14372" xml_f="14376" txt_i="7926" txt_f="7930">and </offsets></italic><xref ref-type="supplementary-material" rid="S3"><offsets xml_i="14434" xml_f="14435" txt_i="7930" txt_f="7931">3</offsets></xref><offsets xml_i="14442" xml_f="14463" txt_i="7931" txt_f="7952">) while the McNemar (</offsets><italic><offsets xml_i="14471" xml_f="14487" txt_i="7952" txt_f="7968">Additional file </offsets></italic><xref ref-type="supplementary-material" rid="S4"><offsets xml_i="14545" xml_f="14546" txt_i="7968" txt_f="7969">4</offsets></xref><italic><offsets xml_i="14561" xml_f="14565" txt_i="7969" txt_f="7973">and </offsets></italic><xref ref-type="supplementary-material" rid="S5"><offsets xml_i="14623" xml_f="14624" txt_i="7973" txt_f="7974">5</offsets></xref><offsets xml_i="14631" xml_f="14761" txt_i="7974" txt_f="8101">) test analyzed the presence of the PPD symptoms. Test, and all results P &lt; 0.05 has been considered statistically significant.</offsets></p><table-wrap id="T2" position="float"><label><offsets xml_i="14809" xml_f="14816" txt_i="8102" txt_f="8109">Table 2</offsets></label><caption><p><offsets xml_i="14836" xml_f="14848" txt_i="8109" txt_f="8121">NNT analysis</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th align="center"><offsets xml_i="14938" xml_f="14945" txt_i="8122" txt_f="8129">Present</offsets></th><th align="center"><offsets xml_i="14969" xml_f="14975" txt_i="8129" txt_f="8135">Absent</offsets></th><th align="center"><offsets xml_i="14999" xml_f="15004" txt_i="8135" txt_f="8140">Total</offsets></th></tr></thead><tbody><tr><td align="left"><bold><offsets xml_i="15056" xml_f="15071" txt_i="8140" txt_f="8155">Given (Group A)</offsets></bold></td><td align="center"><offsets xml_i="15102" xml_f="15105" txt_i="8156" txt_f="8159">138</offsets></td><td align="center"><offsets xml_i="15129" xml_f="15132" txt_i="8160" txt_f="8163">550</offsets></td><td align="center"><offsets xml_i="15156" xml_f="15159" txt_i="8164" txt_f="8167">688</offsets></td></tr><tr><td align="left"><bold><offsets xml_i="15196" xml_f="15215" txt_i="8168" txt_f="8187">Not Given (Group B)</offsets></bold></td><td align="center"><offsets xml_i="15246" xml_f="15249" txt_i="8188" txt_f="8191">148</offsets></td><td align="center"><offsets xml_i="15273" xml_f="15275" txt_i="8192" txt_f="8194">52</offsets></td><td align="center"><offsets xml_i="15299" xml_f="15302" txt_i="8195" txt_f="8198">200</offsets></td></tr><tr><td align="left"><bold><offsets xml_i="15339" xml_f="15344" txt_i="8199" txt_f="8204">Total</offsets></bold></td><td align="center"><offsets xml_i="15375" xml_f="15378" txt_i="8205" txt_f="8208">286</offsets></td><td align="center"><offsets xml_i="15402" xml_f="15405" txt_i="8209" txt_f="8212">602</offsets></td><td align="center"><offsets xml_i="15429" xml_f="15432" txt_i="8213" txt_f="8216">888</offsets></td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td align="left" colspan="2"><bold><offsets xml_i="15526" xml_f="15559" txt_i="8221" txt_f="8254">Risk of Outcome in Treated Group:</offsets></bold></td><td align="right" colspan="2"><offsets xml_i="15601" xml_f="15607" txt_i="8255" txt_f="8261">0,2000</offsets></td></tr><tr><td align="left" colspan="2"><bold><offsets xml_i="15656" xml_f="15689" txt_i="8262" txt_f="8295">Risk of Outcome in Control Group:</offsets></bold></td><td align="right" colspan="2"><offsets xml_i="15731" xml_f="15737" txt_i="8296" txt_f="8302">0,7400</offsets></td></tr><tr><td align="left" colspan="2"><bold><offsets xml_i="15786" xml_f="15810" txt_i="8303" txt_f="8327">Absolute Risk Reduction:</offsets></bold></td><td align="right" colspan="2"><offsets xml_i="15852" xml_f="15858" txt_i="8328" txt_f="8334">0,5400</offsets></td></tr><tr><td align="left" colspan="2"><bold><offsets xml_i="15907" xml_f="15921" txt_i="8335" txt_f="8349">Relative Risk:</offsets></bold></td><td align="right" colspan="2"><offsets xml_i="15963" xml_f="15969" txt_i="8350" txt_f="8356">0,2700</offsets></td></tr><tr><td align="left" colspan="2"><bold><offsets xml_i="16018" xml_f="16041" txt_i="8357" txt_f="8380">Relative Risk Reduction</offsets></bold></td><td align="right" colspan="2"><offsets xml_i="16083" xml_f="16089" txt_i="8381" txt_f="8387">0,7300</offsets></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left" colspan="2"><bold><offsets xml_i="16177" xml_f="16199" txt_i="8389" txt_f="8411">Number Needed To Treat</offsets></bold></td><td align="right" colspan="2"><bold><offsets xml_i="16247" xml_f="16253" txt_i="8412" txt_f="8418">1,8500</offsets></bold></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="16306" xml_f="16357" txt_i="8419" txt_f="8470">Table legend text. Number Needed to Treat Analysis.</offsets></p></table-wrap-foot></table-wrap></sec></sec><sec><title><offsets xml_i="16416" xml_f="16423" txt_i="8473" txt_f="8480">Results</offsets></title><p><offsets xml_i="16434" xml_f="16674" txt_i="8481" txt_f="8721">Before the "active" treatment among 688 subjects, 512 (74.41%) were positive for stress-related psycho physiological disorder (PPD), and in the 200 patients of the "placebo" group these kind of disorders were detected in 150 (75%) subjects.</offsets></p><p><offsets xml_i="16681" xml_f="17222" txt_i="8722" txt_f="9263">After "active" REAC-treatment, only 138 of 512 patients (26.9%) still presented symptoms of stress-related PPD (McNemar Test Chi-Square = 372,003, Asymp. Sig. = 0,000). In terms of percentage, migraine headache and bronchial asthma still remains in about 65% and 30% of these "poor-responder" subjects, respectively, whereas in the "placebo" group, a wider spectrum of symptoms (mainly migraine headaches, essential hypertension, anxious tremors, neck and back pain, chronic pain, insomnia, etc) were observed in 148 of 150 subjects (98.6%).</offsets></p><p><offsets xml_i="17229" xml_f="17307" txt_i="9264" txt_f="9342">In Group A, the TP scores decreased significantly from 122.3 to 96.01, Figure </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="17337" xml_f="17338" txt_i="9342" txt_f="9343">1</offsets></xref><offsets xml_i="17345" xml_f="17589" txt_i="9343" txt_f="9587"> (Wilcoxon Signed Rank Test Z = -22,735, Asymp. Sig (2-tailed) = 0,000); in Group B, the decrease of TP scores from 122.96 to 122.11, was not statistically significant (Wilcoxon Signed Rank Test Z=-0,914, Asymp. Sig (2-tailed) = 0,361), Figure </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="17619" xml_f="17620" txt_i="9587" txt_f="9588">2</offsets></xref><offsets xml_i="17627" xml_f="17635" txt_i="9588" txt_f="9596">, Table </offsets><xref ref-type="table" rid="T3"><offsets xml_i="17667" xml_f="17668" txt_i="9596" txt_f="9597">3</offsets></xref><offsets xml_i="17675" xml_f="17676" txt_i="9597" txt_f="9598">.</offsets></p><fig id="F1" position="float"><label><offsets xml_i="17717" xml_f="17725" txt_i="9599" txt_f="9607">Figure 1</offsets></label><caption><p><bold><offsets xml_i="17751" xml_f="17776" txt_i="9607" txt_f="9632">Box Plot Graphs (treated)</offsets></bold><offsets xml_i="17783" xml_f="17847" txt_i="9632" txt_f="9696">. Box Plot Graphs of the PSM total points of the real treatment.</offsets></p></caption><graphic xlink:href="1477-7525-9-54-1"></graphic></fig><fig id="F2" position="float"><label><offsets xml_i="17953" xml_f="17961" txt_i="9697" txt_f="9705">Figure 2</offsets></label><caption><p><bold><offsets xml_i="17987" xml_f="18012" txt_i="9705" txt_f="9730">Box Plot Graphs (placebo)</offsets></bold><offsets xml_i="18019" xml_f="18076" txt_i="9730" txt_f="9787">. Box Plot Graphs of the PSM total points of the placebo.</offsets></p></caption><graphic xlink:href="1477-7525-9-54-2"></graphic></fig><table-wrap id="T3" position="float"><label><offsets xml_i="18189" xml_f="18196" txt_i="9788" txt_f="9795">Table 3</offsets></label><caption><p><offsets xml_i="18216" xml_f="18232" txt_i="9795" txt_f="9811">PSM test results</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center"><offsets xml_i="18313" xml_f="18321" txt_i="9812" txt_f="9820">Subjects</offsets></th><th align="center"><offsets xml_i="18345" xml_f="18357" txt_i="9820" txt_f="9832">Total points</offsets><break></break><offsets xml_i="18372" xml_f="18380" txt_i="9832" txt_f="9840">PSM Test</offsets></th><th align="center"><offsets xml_i="18404" xml_f="18407" txt_i="9840" txt_f="9843">PPD</offsets><break></break><offsets xml_i="18422" xml_f="18440" txt_i="9843" txt_f="9861">n. of subjects (%)</offsets></th><th align="center"><offsets xml_i="18464" xml_f="18477" txt_i="9861" txt_f="9874">Wilcoxon Test</offsets></th></tr></thead><tbody><tr><td align="center"><bold><offsets xml_i="18531" xml_f="18552" txt_i="9874" txt_f="9895">Group A (n. 688) (t0)</offsets></bold></td><td align="center"><offsets xml_i="18583" xml_f="18597" txt_i="9896" txt_f="9910">122.53 ± 6.747</offsets></td><td align="center"><offsets xml_i="18621" xml_f="18627" txt_i="9911" txt_f="9917">n. 512</offsets></td><td align="center"><offsets xml_i="18651" xml_f="18662" txt_i="9918" txt_f="9929">Asymp. Sig.</offsets><break></break><offsets xml_i="18677" xml_f="18687" txt_i="9929" txt_f="9939">(2-tailed)</offsets><break></break><offsets xml_i="18702" xml_f="18707" txt_i="9939" txt_f="9944">0.000</offsets></td></tr><tr><td align="center"><bold><offsets xml_i="18746" xml_f="18753" txt_i="9945" txt_f="9952">Group A</offsets></bold><break></break><bold><offsets xml_i="18781" xml_f="18785" txt_i="9952" txt_f="9956">(t1)</offsets></bold></td><td align="center"><offsets xml_i="18816" xml_f="18829" txt_i="9957" txt_f="9970">96.01 ± 8.520</offsets></td><td align="center"><offsets xml_i="18853" xml_f="18872" txt_i="9971" txt_f="9990">n. 138 (20% of 512)</offsets></td><td align="center"><offsets xml_i="18896" xml_f="18918" txt_i="9991" txt_f="10010">Z=-22.735 P &lt; 0.005</offsets></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="center"><bold><offsets xml_i="18996" xml_f="19017" txt_i="10012" txt_f="10033">Group B (n. 200) (t0)</offsets></bold></td><td align="center"><offsets xml_i="19048" xml_f="19062" txt_i="10034" txt_f="10048">122.96 ± 7.041</offsets></td><td align="center"><offsets xml_i="19086" xml_f="19092" txt_i="10049" txt_f="10055">n. 150</offsets></td><td align="center"><offsets xml_i="19116" xml_f="19127" txt_i="10056" txt_f="10067">Asymp. Sig.</offsets><break></break><offsets xml_i="19142" xml_f="19152" txt_i="10067" txt_f="10077">(2-tailed)</offsets><break></break><offsets xml_i="19167" xml_f="19172" txt_i="10077" txt_f="10082">0.361</offsets></td></tr><tr><td align="center"><bold><offsets xml_i="19211" xml_f="19218" txt_i="10083" txt_f="10090">Group B</offsets></bold><break></break><bold><offsets xml_i="19246" xml_f="19250" txt_i="10090" txt_f="10094">(t1)</offsets></bold></td><td align="center"><offsets xml_i="19281" xml_f="19295" txt_i="10095" txt_f="10109">122.11 ± 7.450</offsets></td><td align="center"><offsets xml_i="19319" xml_f="19340" txt_i="10110" txt_f="10131">n. 148 (98.6% of 150)</offsets></td><td align="center"><offsets xml_i="19364" xml_f="19385" txt_i="10132" txt_f="10150">Z=-0.914 P &gt; 0.005</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="19431" xml_f="19680" txt_i="10151" txt_f="10397">Table legend text. PSM test results: Total points and Wilcoxon test results obtained in group A and in group B, before (t0) and after (t1) NPPO REAC treatment/placebo. Values of Total points are expressed by means ± Standard Deviation. *P &lt; 0.05.</offsets></p></table-wrap-foot></table-wrap><p><offsets xml_i="19718" xml_f="19846" txt_i="10398" txt_f="10526">There is no significant correlation between the results of the PSM total points before/after Therapy and the age or the gender (</offsets><italic><offsets xml_i="19854" xml_f="19870" txt_i="10526" txt_f="10542">Additional file </offsets></italic><xref ref-type="supplementary-material" rid="S6"><offsets xml_i="19928" xml_f="19929" txt_i="10542" txt_f="10543">6</offsets></xref><offsets xml_i="19936" xml_f="19938" txt_i="10543" txt_f="10545">).</offsets></p></sec><sec><title><offsets xml_i="19960" xml_f="19970" txt_i="10547" txt_f="10557">Discussion</offsets></title><p><offsets xml_i="19981" xml_f="20139" txt_i="10558" txt_f="10716">This study is the evolution in longitudinal terms of a previous study, and it is specifically targeted to assess each one stress-related clusters of PSM test.</offsets></p><p><offsets xml_i="20146" xml_f="20416" txt_i="10717" txt_f="10987">Recent literature data showed that the medical use of electricity, in many kinds of applications, is probably one of the most important alternative to the "typical" psychopharmacological strategies in the management of Mental Disorders, included the stress-related PPD [</offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="20448" xml_f="20450" txt_i="10987" txt_f="10989">21</offsets></xref><offsets xml_i="20457" xml_f="20459" txt_i="10989" txt_f="10991">].</offsets></p><p><offsets xml_i="20466" xml_f="20578" txt_i="10992" txt_f="11104">As pointed out Bruce S. McEwen, the brain is the key organ of the adaptive and maladaptive responses to stress [</offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="20610" xml_f="20612" txt_i="11104" txt_f="11106">22</offsets></xref><offsets xml_i="20619" xml_f="20847" txt_i="11106" txt_f="11334">] because it determines what is threatening and, therefore, potentially stressful, as well as initiating the behavioral, as well as many of the physiological responses to the stressors, which can be either adaptive or damaging [</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="20879" xml_f="20881" txt_i="11334" txt_f="11336">23</offsets></xref><offsets xml_i="20888" xml_f="20889" txt_i="11336" txt_f="11337">-</offsets><xref ref-type="bibr" rid="B25"><offsets xml_i="20921" xml_f="20923" txt_i="11337" txt_f="11339">25</offsets></xref><offsets xml_i="20930" xml_f="21562" txt_i="11339" txt_f="11971">]. All the adaptations are also expressed by changes of brain electrical activity. All neurological functions are governed mainly by two neurotransmitters: the excitatory glutamate and inhibitory gamma amino butyric acid - (GABA). Their release depends on the electrical changes due to ion flows. The REAC, with its exclusive high technology, reshapes these flows. This induces a progressive, stable and successful reorganization of the bioelectric activity of the central nervous system and consequently of the alterated systems and functions due to PPD in our body. We call this reorganization Neuro Psycho Physical Optimization [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="21593" xml_f="21594" txt_i="11971" txt_f="11972">9</offsets></xref><offsets xml_i="21601" xml_f="21602" txt_i="11972" txt_f="11973">-</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="21634" xml_f="21636" txt_i="11973" txt_f="11975">11</offsets></xref><offsets xml_i="21643" xml_f="21644" txt_i="11975" txt_f="11976">,</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="21676" xml_f="21678" txt_i="11976" txt_f="11978">13</offsets></xref><offsets xml_i="21685" xml_f="21686" txt_i="11978" txt_f="11979">-</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="21718" xml_f="21720" txt_i="11979" txt_f="11981">20</offsets></xref><offsets xml_i="21727" xml_f="21729" txt_i="11981" txt_f="11983">].</offsets></p></sec><sec><title><offsets xml_i="21751" xml_f="21762" txt_i="11985" txt_f="11996">Conclusions</offsets></title><p><offsets xml_i="21773" xml_f="22457" txt_i="11997" txt_f="12681">This research highlights the efficacy of NPPO treatment with REAC on PPD cluster of PSM test in non psychiatric subjects. These conditions represent the most comprehensive mental suffering in the general population. Further studies are needed to verify the stability over time when using more than one cycle, although it could be very difficult to obtain and to maintain a selected group, especially after treatment. Our results showed that NPPO treatment with REAC will help to speed up the physiological capability of the organism recovery, optimising the adaptive response to environmental stressors and contributing to the elimination of dysfunctional adaptive responses like PPD.</offsets></p><p><offsets xml_i="22464" xml_f="23265" txt_i="12682" txt_f="13483">Clearly, our research presents several limitations. First, the wide variation and polymorphism of the stress-related symptomatology need to be considered in the global evaluation of our results. Second, it should be considered that REAC treatment is an innovative treatment and these patients could have had great expectations. Third, its administration is almost imperceptible and this characteristic can be the basis of the very little placebo effect. Fourth, the different mean age between the Group A and Group B could somehow conditioning the obtained results: therefore, there will be more reliable results comparing similar groups of age. Finally, a longer period of observation and the administration of further REAC-therapy cycles are necessary to assess the stability of our goals over time.</offsets></p></sec><sec><title><offsets xml_i="23287" xml_f="23306" txt_i="13485" txt_f="13504">Competing interests</offsets></title><p><offsets xml_i="23317" xml_f="23413" txt_i="13505" txt_f="13601">Salvatore Rinaldi and Vania Fontani are the inventors of the Radio Electric Asymmetric Conveyer.</offsets></p></sec><sec><title><offsets xml_i="23435" xml_f="23457" txt_i="13603" txt_f="13625">Authors' contributions</offsets></title><p><offsets xml_i="23468" xml_f="23834" txt_i="13626" txt_f="13992">SR and VF conceived of the study, participated in its design and coordination and in drafting of the manuscript. PM, psychiatrist, for the psychiatric clinical evaluation, LA and AC have critically revised the manuscript, MLM has done data analysis and BR professional statistician, has overseen the data analysis. All authors read and approved the final manuscript.</offsets></p></sec><sec sec-type="supplementary-material"><title><offsets xml_i="23890" xml_f="23912" txt_i="13994" txt_f="14016">Supplementary Material</offsets></title><supplementary-material content-type="local-data" id="S1"><caption><title><offsets xml_i="23994" xml_f="24011" txt_i="14017" txt_f="14034">Additional file 1</offsets></title><p><bold><offsets xml_i="24028" xml_f="24045" txt_i="14035" txt_f="14052">CONSORT Checklist</offsets></bold><offsets xml_i="24052" xml_f="24072" txt_i="14052" txt_f="14072">. Consort checklist.</offsets></p></caption><media xlink:href="1477-7525-9-54-S1.PDF" mimetype="application" mime-subtype="pdf"><caption><p><offsets xml_i="24182" xml_f="24201" txt_i="14073" txt_f="14092">Click here for file</offsets></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S2"><caption><title><offsets xml_i="24322" xml_f="24339" txt_i="14093" txt_f="14110">Additional file 2</offsets></title><p><bold><offsets xml_i="24356" xml_f="24385" txt_i="14111" txt_f="14140">Statistic of Real therapy 688</offsets></bold><offsets xml_i="24392" xml_f="24433" txt_i="14140" txt_f="14181">. Statistic of Real therapy 688 (Group A)</offsets></p></caption><media xlink:href="1477-7525-9-54-S2.PDF" mimetype="application" mime-subtype="pdf"><caption><p><offsets xml_i="24543" xml_f="24562" txt_i="14182" txt_f="14201">Click here for file</offsets></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S3"><caption><title><offsets xml_i="24683" xml_f="24700" txt_i="14202" txt_f="14219">Additional file 3</offsets></title><p><bold><offsets xml_i="24717" xml_f="24749" txt_i="14220" txt_f="14252">Statistic of Placebo control 200</offsets></bold><offsets xml_i="24756" xml_f="24800" txt_i="14252" txt_f="14296">. Statistic of Placebo control 200 (Group B)</offsets></p></caption><media xlink:href="1477-7525-9-54-S3.PDF" mimetype="application" mime-subtype="pdf"><caption><p><offsets xml_i="24910" xml_f="24929" txt_i="14297" txt_f="14316">Click here for file</offsets></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S4"><caption><title><offsets xml_i="25050" xml_f="25067" txt_i="14317" txt_f="14334">Additional file 4</offsets></title><p><bold><offsets xml_i="25084" xml_f="25113" txt_i="14335" txt_f="14364">Statistic of Real therapy 688</offsets></bold><offsets xml_i="25120" xml_f="25160" txt_i="14364" txt_f="14404">. McNemar Test of Real Therapy (Group A)</offsets></p></caption><media xlink:href="1477-7525-9-54-S4.PDF" mimetype="application" mime-subtype="pdf"><caption><p><offsets xml_i="25270" xml_f="25289" txt_i="14405" txt_f="14424">Click here for file</offsets></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S5"><caption><title><offsets xml_i="25410" xml_f="25427" txt_i="14425" txt_f="14442">Additional file 5</offsets></title><p><bold><offsets xml_i="25444" xml_f="25476" txt_i="14443" txt_f="14475">Statistic of Placebo control 200</offsets></bold><offsets xml_i="25483" xml_f="25526" txt_i="14475" txt_f="14518">. McNemar Test of Placebo control (Group B)</offsets></p></caption><media xlink:href="1477-7525-9-54-S5.PDF" mimetype="application" mime-subtype="pdf"><caption><p><offsets xml_i="25636" xml_f="25655" txt_i="14519" txt_f="14538">Click here for file</offsets></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S6"><caption><title><offsets xml_i="25776" xml_f="25793" txt_i="14539" txt_f="14556">Additional file 6</offsets></title><p><bold><offsets xml_i="25810" xml_f="25839" txt_i="14557" txt_f="14586">Statistic of Real therapy 688</offsets></bold><offsets xml_i="25846" xml_f="25915" txt_i="14586" txt_f="14655">. Correlation between PSM Total points and subgroups (age and gender)</offsets></p></caption><media xlink:href="1477-7525-9-54-S6.PDF" mimetype="application" mime-subtype="pdf"><caption><p><offsets xml_i="26025" xml_f="26044" txt_i="14656" txt_f="14675">Click here for file</offsets></p></caption></media></supplementary-material></sec></body><back><sec><title>Acknowledgements</title><p>The authors thank Doctors Stefania Bini and Giorgio Saragò for their helpful discussions.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Dirkzwager</surname><given-names>AJ</given-names></name><name><surname>Verhaak</surname><given-names>PF</given-names></name><article-title>Patients with persistent medically unexplained symptoms in general practice: characteristics and quality of care</article-title><source>BMC Fam Pract</source><year>2007</year><volume>8</volume><fpage>33</fpage><pub-id pub-id-type="doi">10.1186/1471-2296-8-33</pub-id><pub-id pub-id-type="pmid">17540013</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Reid</surname><given-names>S</given-names></name><name><surname>Wessely</surname><given-names>S</given-names></name><name><surname>Crayford</surname><given-names>T</given-names></name><name><surname>Hotopf</surname><given-names>M</given-names></name><article-title>Medically unexplained symptoms in frequent attenders of secondary health care: retrospective cohort study</article-title><source>BMJ</source><year>2001</year><volume>322</volume><fpage>767</fpage><pub-id pub-id-type="doi">10.1136/bmj.322.7289.767</pub-id><pub-id pub-id-type="pmid">11282861</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Lemyre LT</surname><given-names>R</given-names></name><article-title>Mesure du stress psychologique. Se sentir stressé-e</article-title><source>Rev Canad Sci Comport</source><year>1988</year><volume>20</volume><fpage>302</fpage><lpage>321</lpage></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Trovato</surname><given-names>GM</given-names></name><name><surname>Catalano</surname><given-names>D</given-names></name><name><surname>Martines</surname><given-names>GF</given-names></name><name><surname>Spadaro</surname><given-names>D</given-names></name><name><surname>Di Corrado</surname><given-names>D</given-names></name><name><surname>Crispi</surname><given-names>V</given-names></name><name><surname>Garufi</surname><given-names>G</given-names></name><name><surname>Di Nuovo</surname><given-names>S</given-names></name><article-title>Psychological stress measure in type 2 diabetes</article-title><source>Eur Rev Med Pharmacol Sci</source><year>2006</year><volume>10</volume><fpage>69</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">16705951</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="book"><collab>APA</collab><source>Diagnostic and statistic manual of mental disorders</source><year>2000</year><publisher-name>Washington DC: American Psychiatric Press</publisher-name></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Lemyre</surname><given-names>L</given-names></name><name><surname>Tessier</surname><given-names>R</given-names></name><article-title>Measuring psychological stress. Concept, model, and measurement instrument in primary care research</article-title><source>Can Fam Physician</source><year>2003</year><volume>49</volume><fpage>1159</fpage><lpage>1160</lpage><comment>1166-1158</comment><pub-id pub-id-type="pmid">14526870</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="other"><name><surname>Rinaldi</surname><given-names>S</given-names></name><name><surname>Fontani</surname><given-names>V</given-names></name><article-title>Radioelectric Asymmetric Conveyer for therapeutic use</article-title><source>Book Radioelectric Asymmetric Conveyer for therapeutic use</source><year>2000</year><comment>(Editor ed.^eds.), A61N 1/32 (2006.01); A61N 1/40 (2006.01); A61N 5/00 (2006.01) edition. City: Rinaldi, S., Fontani, V</comment></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="other"><name><surname>Rinaldi</surname><given-names>S</given-names></name><name><surname>Fontani</surname><given-names>V</given-names></name><article-title>Radioelectric Asymmetric Conveyer for therapeutic use</article-title><source>Book Radioelectric Asymmetric Conveyer for therapeutic use</source><year>2001</year><fpage>5</fpage><comment>(Editor ed.^eds.), A61F007/00; A61F007/12 edition. pp. 5. City: Rinaldi, S., Fontani, V</comment></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Castagna</surname><given-names>A</given-names></name><name><surname>Rinaldi</surname><given-names>S</given-names></name><name><surname>Fontani</surname><given-names>V</given-names></name><name><surname>Aravagli</surname><given-names>L</given-names></name><name><surname>Mannu</surname><given-names>P</given-names></name><name><surname>Margotti</surname><given-names>ML</given-names></name><article-title>Does Osteoarthritis Of The Knee Also Have A Psychogenic Component? Psycho-emotional Treatment With a Radio-electric Device vs. Intra-articular Injection Of Sodium Hyaluronate: An Open-label, Naturalistic Study</article-title><source>Acupuncture &amp; Electro-Therapeutics Res, Int J</source><year>2010</year><volume>35</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">21776291</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Collodel</surname><given-names>G</given-names></name><name><surname>Moretti</surname><given-names>E</given-names></name><name><surname>Fontani</surname><given-names>V</given-names></name><name><surname>Rinaldi</surname><given-names>S</given-names></name><name><surname>Aravagli</surname><given-names>L</given-names></name><name><surname>Sarago</surname><given-names>G</given-names></name><name><surname>Capitani</surname><given-names>S</given-names></name><name><surname>Anichini</surname><given-names>C</given-names></name><article-title>Effect of emotional stress on sperm quality</article-title><source>Indian Journal of Medical Research</source><year>2008</year><volume>128</volume><fpage>254</fpage><lpage>261</lpage><pub-id pub-id-type="pmid">19052335</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Mannu</surname><given-names>P</given-names></name><name><surname>Rinaldi</surname><given-names>S</given-names></name><name><surname>Fontani</surname><given-names>V</given-names></name><name><surname>Castagna</surname><given-names>A</given-names></name><name><surname>Lotti Margotti</surname><given-names>M</given-names></name><article-title>Radio Electric Treatment Vs. Es-Citalopram In The Treatment Of Panic Disorders Associated With Major Depression: An Open-Label, Naturalistic Study</article-title><source>Acupuncture &amp; Electro-Therapeutics Res, Int J</source><year>2009</year><volume>34</volume><fpage>135</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">21776291</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="book"><name><surname>Rinaldi</surname><given-names>S</given-names></name><name><surname>Fontani</surname><given-names>V</given-names></name><name><surname>Aravagli</surname><given-names>L</given-names></name><article-title>Ruolo ed evidenze cliniche della CRM Terapia nelle alterazioni stress correlate</article-title><source>Rapporto Nazionale 2007 sulla Condizione ed il Pensiero degli Anziani</source><year>2007</year><publisher-name>Rome: Ageing Society-Osservatorio Terza Età</publisher-name><fpage>1587</fpage><lpage>1611</lpage></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Rinaldi</surname><given-names>S</given-names></name><name><surname>Fontani</surname><given-names>V</given-names></name><name><surname>Aravagli</surname><given-names>L</given-names></name><name><surname>Mannu</surname><given-names>P</given-names></name><article-title>Psychometric evaluation of a radio electric auricular treatment for stress related disorders: a double-blinded, placebo-controlled controlled pilot study</article-title><source>Health and Quality of Life Outcomes</source><year>2010</year><volume>8</volume><fpage>31</fpage><pub-id pub-id-type="doi">10.1186/1477-7525-8-31</pub-id><pub-id pub-id-type="pmid">20302662</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Rinaldi</surname><given-names>S</given-names></name><name><surname>Fontani</surname><given-names>V</given-names></name><name><surname>Aravagli</surname><given-names>L</given-names></name><name><surname>Margotti</surname><given-names>ML</given-names></name><article-title>Psychological and symptomatic stress-related disorders with radio-electric treatment: psychometric evaluation</article-title><source>Stress and Health</source><year>2010</year><volume>26</volume><fpage>350</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1002/smi.1298</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Mannu</surname><given-names>P</given-names></name><name><surname>Rinaldi</surname><given-names>S</given-names></name><name><surname>Fontani</surname><given-names>V</given-names></name><name><surname>Castagna</surname><given-names>A</given-names></name><article-title>Radio electric asymmetric brain stimulation in the treatment of behavioral and psychiatric symptoms in Alzheimer Disease</article-title><source>Clinical Interventions in Aging</source><year>2011</year><volume>6</volume></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Castagna</surname><given-names>A</given-names></name><name><surname>Rinaldi</surname><given-names>S</given-names></name><name><surname>Fontani</surname><given-names>V</given-names></name><name><surname>Mannu</surname><given-names>P</given-names></name><name><surname>Margotti</surname><given-names>ML</given-names></name><article-title>A comparison of two different treatments for coxarthrosis: local hyperthermia versus radio electric asymmetrical brain stimulation. A retrospective case series</article-title><source>Clinical Interventions in Aging</source><year>2011</year><volume>6</volume></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Bourget Olivieri</surname><given-names>E</given-names></name><name><surname>Vecchiato</surname><given-names>C</given-names></name><name><surname>Ignaccolo</surname><given-names>N</given-names></name><name><surname>Mannu</surname><given-names>P</given-names></name><name><surname>Castagna</surname><given-names>A</given-names></name><name><surname>Fontani</surname><given-names>V</given-names></name><name><surname>Rinaldi</surname><given-names>S</given-names></name><article-title>Radio electric brain stimulation in the treatment of generalized anxiety disorder comorbid with major depression in a public psychiatric hospital: a pilot study</article-title><source>Neuropsychiatric Disease and Treatment</source><year>2011</year><volume>7</volume></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Rinaldi</surname><given-names>S</given-names></name><name><surname>Fontani</surname><given-names>V</given-names></name><name><surname>Moretti</surname><given-names>E</given-names></name><name><surname>Rosettani</surname><given-names>B</given-names></name><name><surname>Aravagli</surname><given-names>L</given-names></name><name><surname>Sarago</surname><given-names>G</given-names></name><name><surname>Collodel</surname><given-names>G</given-names></name><article-title>A new approach on stress-related depression &amp; anxiety: Neuro-Psycho-Physical-Optimization with Radio Electric Asymmetric-Conveyer</article-title><source>Indian J Med Res</source><year>2010</year><volume>132</volume><fpage>189</fpage><lpage>194</lpage><pub-id pub-id-type="pmid">20716819</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Castagna</surname><given-names>A</given-names></name><name><surname>Rinaldi</surname><given-names>S</given-names></name><name><surname>Fontani</surname><given-names>V</given-names></name><name><surname>Mannu</surname><given-names>P</given-names></name><article-title>Radioelectric asymmetric brain stimulation and lingual apex repositioning in patients with atypical deglutition</article-title><source>Radioelectric asymmetric brain stimulation and lingual apex repositioning in patients with atypical deglutition</source><year>2011</year><volume>4</volume><fpage>209</fpage><lpage>213</lpage></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Mannu</surname><given-names>P</given-names></name><name><surname>Rinaldi</surname><given-names>S</given-names></name><name><surname>Fontani</surname><given-names>V</given-names></name><name><surname>Castagna</surname><given-names>A</given-names></name><article-title>Long-term treatment of bipolar disorder with a radioelectric asymmetric conveyor</article-title><source>Neuropsychiatric Disease and Treatment</source><year>2011</year><volume>7</volume><fpage>373</fpage><lpage>379</lpage></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Daban</surname><given-names>C</given-names></name><name><surname>Martinez-Aran</surname><given-names>A</given-names></name><name><surname>Cruz</surname><given-names>N</given-names></name><name><surname>Vieta</surname><given-names>E</given-names></name><article-title>Safety and efficacy of Vagus Nerve Stimulation in treatment-resistant depression. A systematic review</article-title><source>J Affect Disord</source><year>2008</year><volume>110</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2008.02.012</pub-id><pub-id pub-id-type="pmid">18374988</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>McEwen</surname><given-names>BS</given-names></name><article-title>Physiology and neurobiology of stress and adaptation: central role of the brain</article-title><source>Physiol Rev</source><year>2007</year><volume>87</volume><fpage>873</fpage><lpage>904</lpage><pub-id pub-id-type="doi">10.1152/physrev.00041.2006</pub-id><pub-id pub-id-type="pmid">17615391</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>McEwen</surname><given-names>BS</given-names></name><article-title>Protective and damaging effects of stress mediators</article-title><source>N Engl J Med</source><year>1998</year><volume>338</volume><fpage>171</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1056/NEJM199801153380307</pub-id><pub-id pub-id-type="pmid">9428819</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>McEwen</surname><given-names>BS</given-names></name><article-title>Protective and damaging effects of stress mediators: the good and bad sides of the response to stress</article-title><source>Metabolism</source><year>2002</year><volume>51</volume><fpage>2</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1053/meta.2002.33183</pub-id><pub-id pub-id-type="pmid">12040533</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>McEwen</surname><given-names>BS</given-names></name><article-title>Protective and damaging effects of stress mediators: central role of the brain</article-title><source>Prog Brain Res</source><year>2000</year><volume>122</volume><fpage>25</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">10737048</pub-id></mixed-citation></ref></ref-list></back></article>